Abstract: Most infections by human papillomaviruses (HPVs) are non-persistent. Yet, for HPVs, as 1 for many other oncoviruses, there is a striking gap between our detailed understanding of chronic 2 infections and our limited data on the early stages of infection. Here we argue that studying the Keywords: clearance; persistence; latency; fertility; virome; warts; cancer; evolution; 12 immunotherapies; vaccination
Bar color intensity reflects the prevalence of cervical cancer in the corresponding age class (and hence the focus of current research). Data should be read as follows, using the 30-34 years of age as an example: in less developed regions, among the 228 million women in the age class, 40 million (17,8%) display a normal cytology but are actually infected by HPVs, and 30 thousand (0,013%) suffer from cervical cancer, while in more developed regions among the 42 million women in the age class, 4.3 million (10,2%) display a normal cytology but are actually infected by HPVs, and 6 thousand (0,015%) suffer from cervical cancer. Data correspond to HPV prevalence in women with normal cytology, as estimated in the HPV information center (http://hpvcentre.net/, [5] ). Overall HPV prevalence values will be actually larger, as they will include women with abnormal cytology. No data were available for HPV prevalence in women below 15 years of age. Demographic data correspond to the UN projections for 2015 (note the shift in the logarithmic scale for the left and the right sides).
infection. Why some anogenital infections persist and progress to cancer remains largely unresolved (Box 1).
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We know that HPV infections concur with a local anti-inflammatory environment, and that although 101 the adaptive immune response is very efficient at clearing the infection, its activation is variable and 102 not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was . http://dx.doi.org/10.1101/144576 doi: bioRxiv preprint first posted online May. 31, 2017;  sometimes insufficient to prevent future re-infections [20, 26, 27] Overall, vaccination against HPVs will undoubtedly have a strong and highly desirable impact in 201 disease prevention, but it will create novel host environments to which the viruses may adapt.
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Evaluating the potential for HPV evolution, requires genomic data of intra-and inter-individual 
